基于FDA MAUDE数据库对Jetstream斑块旋切术治疗外周动脉疾病真实世界安全性的洞察
本研究检索FDA MAUDE数据库中2019年1月1日至2021年12月31日关于Jetstream斑块旋切系统的不良事件报告,排除重复及信息不足报告后分析500份报告。最常见患者并发症为栓塞(22例;4.4%)、夹层(17例;3.4%)、血管穿孔(12例;2.4%)及患者体内装置断裂(6例;1.2%)。按CIRSE分类,多数事件无术后后遗症(475例;95%)。
要点
- 栓塞(22例;4.4%)与夹层(17例;3.4%)为最常见患者并发症。
- 装置失败常见模式为导丝缠绕(134例;27%)与刀片旋转丢失(116例;23%)。
- 按CIRSE分类,475例(95%)事件无术后后遗症。
核心结论
- 本研究凸显了Jetstream斑块旋切系统在真实世界实践中遇到的重要不良事件,有助于理解其安全性特征和失败模式,并可能帮助指导产品设计改进和制造商-用户培训。
- 作者认为更需要可借助将装置退回制造商来辅助的根因分析。
研究设计与样本
- 研究检索FDA MAUDE数据库2019年1月1日至2021年12月31日关于Jetstream斑块旋切系统(Boston Scientific)治疗外周动脉疾病的不良事件报告,排除重复及信息不足报告后共分析500份报告。
- 不良事件分类为患者并发症、装置故障或两者兼有,并使用欧洲心血管与介入放射学会(CIRSE)不良事件分类系统进行分级。
主要发现
- 最常见患者并发症为栓塞(22例;4.4%)、夹层(17例;3.4%)、血管穿孔(12例;2.4%)及患者体内装置断裂(6例;1.2%)。
- 最常见装置失败模式为装置在导丝上缠绕(134例;27%)、刀片旋转丢失(116例;23%)、抽吸丢失(99例;20%)及机械损坏(57例;11%)。
- 按CIRSE不良事件分类,多数事件无术后后遗症(475例;95%),其次为需要延长观察(14例;2.8%)及无长期后遗症的术后治疗(10例;2.0%)。
- 106台装置(21%)被退回制造商进行分析。
关键数值与推荐
- CIRSE分类无术后后遗症475例(95%)、需要延长观察14例(2.8%)、无长期后遗症的术后治疗10例(2.0%)。
临床怎么用
- 作者认为MAUDE数据库有助于捕获和描述传统临床研究中通常未描述的装置失败/故障模式,可能为产品设计改进和制造商-用户培训提供有价值信息。
- 作者希望本研究通过增进对Jetstream斑块旋切系统安全性特征的了解,可能帮助医生和患者就外周动脉疾病治疗选择做出更知情的决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rotational atherectomy has shown promise as an adjunctive therapy to percutaneous transluminal angioplasty (PTA) and stenting for the treatment of peripheral arterial disease (PAD). However, published data regarding the safety of these devices are limited. The Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database collects reports of adverse event for medical devices. We present 3 years of MAUDE adverse events data for the Jetstream Atherectomy System (Boston Scientific) for the treatment of PAD. MATERIALS AND METHODS: We searched MAUDE from January 1, 2019 to December 31, 2021. Duplicate reports and those with insufficient information were excluded, leaving a total of 500 reports for analysis. Adverse events were categorized as either patient complication, device malfunction, or both. Adverse events were classified using the Cardiovascular and Interventional Radiological Society of Europe's (CIRSE) classification system for adverse events. RESULTS: The most common patient complications were embolism (22; 4.4%), dissection (17; 3.4%), vessel perforation (12; 2.4%), and device fracture in the patient (6; 1.2%). The most common modes of device failure were entrapment of the device on the guidewire (134; 27%), loss of blade rotation (116; 23%), loss of aspiration (99; 20%), and mechanical damage (57; 11%). As per the CIRSE adverse events classification, most events had no post-procedural sequelae (475; 95%), followed by those requiring prolonged observation (14; 2.8%), and post-procedural therapy without long-term sequelae (10; 2.0%). One hundred six devices (21%) were returned for manufacturer analysis. CONCLUSION: We highlight important adverse events encountered in real-world practice with the Jetstream Atherectomy System. This analysis provides further understanding of the safety profile and modes of failure of Jetstream, and could help guide improvements in product design and manufacturer-user training. There is greater need for root-cause analysis that can aided by returning devices to the manufacturer.Clinical ImpactWe highlight important adverse events encountered in real-world practice with the Jetstream Atherectomy System. The MAUDE database is useful for capturing and characterizing modes of device failure/malfunction not typically described in conventional clinical studies. This may provide valuable information to help guide improvements in product design and manufacturer-user training. This information could also potentially be useful in helping establish manufacturer and product liability in the setting of medicolegal claims. We hope that by contributing to the growing understanding of the safety profile of the Jetstream Atherectomy System, our study may help physicians and patients come to more informed decisions regarding treatment options for PAD.
引用
- Min A, Alkhalifa F, Ahrari A, et al. Insights From the FDA's MAUDE Database Regarding the Real-World Safety of Jetstream Atherectomy for Peripheral Arterial Disease. J Endovasc Ther. 2023. PMID: 37750495. doi:10.1177/15266028231202718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。